102 related articles for article (PubMed ID: 9225366)
1. The in vivo effects of interleukin-3 on histamine levels in non-Hodgkin's lymphoma patients.
Hovgaard DJ; Stahl Skov P; Nissen NI
Pharmacol Toxicol; 1997 Jun; 80(6):290-4. PubMed ID: 9225366
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas.
Hovgaard D; Nissen NI
Leuk Lymphoma; 1992 Jun; 7(3):217-24. PubMed ID: 1477649
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
Tanosaki R; Okamoto S; Akatsuka N; Ishida A; Michikawa N; Masuda Y; Uchida H; Murata M; Kizaki M; Ikeda Y
Cancer; 1994 Oct; 74(7):1939-44. PubMed ID: 7521788
[TBL] [Abstract][Full Text] [Related]
4. Effects of interleukin-3 following chemotherapy of non-Hodgkin's lymphoma. A prospective, controlled phase I/II study.
Hovgaard DJ; Nissen NI
Eur J Haematol; 1995 Feb; 54(2):78-84. PubMed ID: 7698300
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor administered in vivo after high-dose cyclophosphamide cancer chemotherapy: effect on hematopoiesis and microenvironment in human bone marrow.
Orazi A; Cattoretti G; Schiró R; Siena S; Bregni M; Di Nicola M; Gianni AM
Blood; 1992 May; 79(10):2610-9. PubMed ID: 1586713
[TBL] [Abstract][Full Text] [Related]
6. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial.
Kaku K; Takahashi M; Moriyama Y; Nakahata T; Masaoka T; Yoshida Y; Shibata A; Kaneko T; Miwa S
Leuk Lymphoma; 1993 Oct; 11(3-4):229-38. PubMed ID: 8260897
[TBL] [Abstract][Full Text] [Related]
8. The tolerability of continuous intravenous infusion of interleukin-3 after DHAP chemotherapy in patients with relapsed malignant lymphoma. A phase-I study.
Raemaekers JM; van Imhoff GW; Verdonck LF; Hessels JA; Fibbe WE
Ann Hematol; 1993 Oct; 67(4):175-81. PubMed ID: 8218538
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma.
Hovgaard DJ; Mortensen BT; Nissen NI
Br J Haematol; 1995 Oct; 91(2):367-73. PubMed ID: 8547077
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
Bergmann L; Karakas T; Knuth A; Lautenschläger G; Mitrou PS; Hoelzer D
Eur J Cancer; 1995 Dec; 31A(13-14):2164-8. PubMed ID: 8652236
[TBL] [Abstract][Full Text] [Related]
11. Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study.
Ganser A; Lindemann A; Ottmann OG; Seipelt G; Hess U; Geissler G; Kanz L; Frisch J; Schulz G; Herrmann F
Blood; 1992 May; 79(10):2583-91. PubMed ID: 1586711
[TBL] [Abstract][Full Text] [Related]
12. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study.
Fay JW; Lazarus H; Herzig R; Saez R; Stevens DA; Collins RH; Piñeiro LA; Cooper BW; DiCesare J; Campion M
Blood; 1994 Oct; 84(7):2151-7. PubMed ID: 7919329
[TBL] [Abstract][Full Text] [Related]
13. Effect of allergen-specific immunotherapy on recombinant human interleukin 3-mediated amplification of allergen-induced basophil histamine release.
Kowal K; Nolte H; Skov PS; DuBuske LM
Allergy Asthma Proc; 2005; 26(6):456-62. PubMed ID: 16541969
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
Sawada KI; Sato N; Kohno M; Hannda H; Yasukouchi T; Tanngo M; Hirayama A; Koike T
Leuk Lymphoma; 1995 Dec; 20(1-2):103-9. PubMed ID: 8750630
[TBL] [Abstract][Full Text] [Related]
15. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study.
Hovgaard DJ; Nissen NI
J Clin Oncol; 1992 Mar; 10(3):390-7. PubMed ID: 1740678
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
[TBL] [Abstract][Full Text] [Related]
17. Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
Engelhard M; Gerhartz H; Brittinger G; Engert A; Fuchs R; Geiseler B; Gerhartz D; Haunauske AR; Hartlapp HJ; Huhn D
Ann Oncol; 1994; 5 Suppl 2():123-5. PubMed ID: 7515644
[TBL] [Abstract][Full Text] [Related]
18. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study.
Postmus PE; Gietema JA; Damsma O; Biesma B; Limburg PC; Vellenga E; de Vries EG
J Clin Oncol; 1992 Jul; 10(7):1131-40. PubMed ID: 1318953
[TBL] [Abstract][Full Text] [Related]
19. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma.
Fay JW; Bernstein SH
Semin Oncol; 1996 Apr; 23(2 Suppl 4):22-7. PubMed ID: 8600545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
